Outpatient pain service in trauma and orthopaedic surgery.

INTRODUCTION: Chronic pain is a common complication after surgery and trauma. The incidence of chronic pain may potentially be reduced by effective management of severe acute pain, in hospital and during the subacute post-operative phase at home. METHODS: This was a cohort study from an outpatient follow-up service for patients with pain at discharge after orthopaedic surgery and trauma in a level 1 university hospital setting. The patients' charts were reviewed. Demographics, diagnosis and treatment were registered. The objective of this study was to describe the first five years of experience with this service. RESULTS: A total of 261 patients were included. The median age was 39 (interquartile range (IQR): 26-76) years, and 53% were men. The median pain duration was ten (IQR: 5-22) months. Neuropathic pain was diagnosed in 83% of patients. Complex regional pain syndrome was diagnosed in 10% and suspected in 8%. Before the consultation, 48% were using paracetamol and/or non-steroid anti-inflammatory drugs (NSAIDs), 25% opioids, and 36% used gabapentioids or antidepressants. After their consultation, only 13% used paracetamol and/or NSAIDs and 8% opioids, whereas 86% were treated with gabapentinoids or antidepressants. A plan for opioid weaning was provided for all patients if opioids were continued (8%). CONCLUSIONS: Establishing an outpatient pain service for persistent pain after surgery and trauma may encourage the use of analgesia regimens that are in accordance with international guidelines and ensure that opioids are not continued inappropriately. FUNDING: None. TRIAL REGISTRATION: Not relevant.

[Opioids for chronic non-malignant pain].

In recent years, the use of opioids in Denmark has been under scrutiny due to various government measures to reduce consumption, greater media focus and Denmark's relatively larger consumption of opioids compared with the Nordic neighbours. Consequently, opioid prescriptions in Denmark have declined since 2017. A more nuanced approach to opioid treatment for non-malignant chronic pain, which includes individualised treatment as well as enhanced interdisciplinary collaboration, is required as argued in this review.

Combination treatment of neuropathic pain: Danish expert recommendations based on a Delphi process.

BACKGROUND: Current Danish treatment algorithms for pharmacological treatment of neuropathic pain (NeP) are tricyclic antidepressants (TCA), gabapentin and pregabalin as first-line treatment for the most common NeP conditions. Many patients have insufficient pain relief on monotherapy, but combination therapy had not been included in guidelines until recently. Based on clinical empiricism and scientific evidence, a Delphi consensus process provided a consolidated guidance on pharmacological combination treatment of NeP. METHODS: A two-round virtual internet-based Delphi process with 6 Danish pain specialists was undertaken. In the first round, questions were answered individually and anonymously, whereas in the second round, the panel openly discussed first round's summary of outcomes. Combinations of pharmacological pain treatments, that is, pregabalin/gabapentin, TCAs, serotonin-norepinephrine reuptake inhibitors (SNRIs), selective serotonin reuptake inhibitors, opioids, other antiepileptics and cutaneous patches, were assessed based on both scientific and clinical practice experiences. The Centers for Disease Control and Prevention (CDC) grading system was used for evidence rating. RESULTS: Combination of pregabalin/gabapentin with TCA is useful in patients who do not gain sufficient pain relief or tolerate either drug in high doses, or to improve sleep disturbance. Also, combination of pregabalin/gabapentin and SNRIs is reasonably well documented and experienced by some experts to result in sufficient pain relief and fewer side effects than monotherapy. Good evidence on efficacy was found for the combination of pregabalin/gabapentin or TCAs and opioids, which was also frequently used in clinical practice. The evidence for combining TCAs and SNRIs is insufficient, although sometimes used in clinical practice despite the risk of serotonin syndrome. For localized NeP, combination therapy with cutaneous patches should be considered. There was insufficient scientific evidence for any pharmacologic combination therapies with selective serotonin reuptake inhibitors - as well as for other potential combinations. CONCLUSIONS: The study revealed that combination therapy is widely used in clinical practice and supported by some scientific evidence. However, further studies are needed.

[Survival after oral poisoning with insecticide against moles containing aluminium phosphide]. / Overlevelse efter peroral forgiftning med muldvarpebekæmpelsesmiddel indeholdende aluminiumfosfid.

A 31-year-old man presented with abdominal pain and vomiting with a smell of garlic and rotten fish. He was brought to the ER being circulatory affected, metabolic acidotic and he developed more episodes of arrhythmia. Oral poisoning with aluminium phosphide is a very serious condition due to release of the toxic phosphine gas. Treatment is symptomatic. To avoid contamination of the staff is it important to use air-tight containers for excretions and furthermore to use chemical clothing and breathing protection.

[Treatment of reflex dystrophy with continuous peripheral nerve block]. / Behandling af refleksdystrofi med kontinuerlig perifer nerveblokade.

Physiotherapy is an important part of the treatment of reflex dystrophy or Complex Regional Pain Syndrome (CRPS)-type I, but this treatment is very painful. We report two cases of reflex dystrophy: a child with recurrent episodes and an adult. Both patients were treated with continuous peripheral nerve block in addition to physiotherapy. The method allows complete pain relief. At follow up (at 2 and 5 months) the results were excellent. By decreasing pain and thereby improving the ability to tolerate physical therapy, this method may have an advantage compared to other treatment modalities.